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Abstract Therapeutic drug monitoring (TDM) involves the
measurement of plasma or serum drug concentration to adapt
dosages to achieve predefined target concentrations that are
associated with optimal clinical response while minimizing
the chance of encountering toxicity. Many papers in the field
of antifungal drugs have focused on the evidence that supports
the use of TDM thereby emphasizing the breakpoints or target
concentrations in general literature. This review focuses on the
process of TDM to inform health care workers on the funda-
ments and prerequisites that safeguard the good application of
TDM. Knowledge on the complete process of TDM including
pharmacokinetics (and relevant covariates), pharmacodynam-
ic aspects, trials that are necessary to provide us with evidence,
translation of knowledge to other populations and pathogens,
and implications for the pre-analytical, analytical, and post-
analytical phases (the process of TDM) are discussed in rele-
vant detail. For each individual step, recommendations are
made for the readers. We believe this will be a valuable re-
source and to be of added value to the many papers that focus
on relations between exposure and efficacy or toxicity. It will
help to achieve greater benefit of TDM.
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Introduction
Currently, three classes of antifungal drugs (i.e., triazoles,
echinocandins, and polyenes) are available to the clinician,
offering a broader antifungal coverage and/or improved toler-
ability beyond the initially developed agents in the polyene
and triazole classes such as conventional amphotericin B, flu-
conazole, and itraconazole. Antifungal agents are used either
prophylactically [1, 2], empirically, or for targeted therapy [3]
for invasive fungal infections. Depending on the strategy cho-
sen, different drugs can be used [4, 5].
Clinical pharmacology encompasses pharmacokinetics and
pharmacodynamics. Pharmacokinetics is the study of absorp-
tion, distribution, metabolism, and excretion of the drug by the
body, whereas pharmacodynamics is the study of the relation-
ship between drug concentrations and drug activity [6].
Pharmacodynamic studies in infectious diseases are related
to the activity of the drug against the pathogen.
Pharmacodynamics is more than the study of efficacy, it also
encompasses the study of drug concentrations in relation to
adverse effects that occur. This difference is relevant because
the pharmacodynamic parameters associated with efficacy
(against the pathogen) may be different from those that define
safety (of the patient).
Success of antifungal therapy depends upon the pharmaco-
kinetic and pharmacodynamic properties of the drugs used.
There is substantial intra- and interindividual variation in
pharmacokinetics and factors causing this variation are not
fully known. To truly individualize therapy, all these pharma-
cokinetic factors must be elucidated in order to adapt drug
doses to the individual and achieve optimal antifungal con-
centrations. Clearly, knowledge on the pharmacodynamics of
antifungal drugs is also needed to define the optimal or target
concentrations that must be achieved. Therapeutic drug mon-
itoring (TDM) is a strategy to tailor the individuals’ exposure
This article is part of the Topical Collection on Pharmacology and
Pharmacodynamics of Antifungal Agents
* Roger J. M. Brüggemann
roger.bruggemann@radboudumc.nl
1 Department of Pharmacy, Radboud University Medical Center, 864,
PO BOX 9101, 6500 HB Nijmegen, The Netherlands
2 Radboud Institute for Health Sciences, Nijmegen, The Netherlands
Curr Fungal Infect Rep (2015) 9:122–129
DOI 10.1007/s12281-015-0224-3
by assessing a patient’s serum or plasma concentration and
subsequently adjusting the dosing regimen. TDM integrates
pharmacokinetic and pharmacodynamic knowledge at an in-
dividual patient level. Over the past decade, much evidence
has been published supporting a role for TDM in the class of
azole antifungal drugs [7–17].
TDM is increasingly considered a standard of care for an-
tifungal therapy for certain drug-pathogen combinations.
Recently, we have reviewed the underlying concepts and in-
dications as well as clinical breakpoints for TDM as a com-
ponent of antifungal therapy [18, 19]. Also, guidelines such as
the upcoming ESCMID guideline on the treatment of
Aspergillus infections and the ECIL guidelines will cover
the role of TDM (personal communication).
This review provides clinicians the fundaments and prereq-
uisites that safeguard the proper application of TDM. We be-
lieve this will be a valuable resource and to be of added value
to the many papers focusing on relations between exposure
and efficacy or toxicity. For that purpose, several important
steps in the process of TDM will be touched upon including
the need to have solid information on pharmacokinetics (and
relevant covariates), pharmacodynamic aspects, trials that are
necessary to provide us with evidence, translation of knowl-
edge to other populations and pathogens, and implications for
the pre-analytical, analytical, and post-analytical phases (the
process of TDM). Every step has to be controlled to the best
optimal extent to use this diagnostic service in its best possible
way. The focus will be on the triazole agents voriconazole,
posaconazole, and the recently licensed isavuconazole.
TDM of Antifungal Drugs
For TDM to be useful, it has to fulfill several criteria [20].
Most importantly, there should be large interindividual vari-
ability in pharmacokinetics; a good relationship should exist
between drug concentrations and effect, a target range should
be defined, and nomore direct intermediate measure of patient
response should be available. Ideally, prospective randomized
controlled clinical trials should be performed to validate pro-
posed target values and the clinical utility of TDM.
Many anti-infective drugs meet these criteria and TDM of
these drugs is widely applied [21–23]. TDM of antifungals is,
therefore, not a new concept. Evidence supporting TDM for
the triazoles voriconazole and posaconazole has materialized
over the past decade. Evidence of a possible role for TDM of
voriconazole first emerged in 2005 and has since continually
grown in favor of TDM [24, 25].
For posaconazole, the debate on TDM is still ongoing [7,
17, 26]. With the marketing of the new intravenous formula-
tion and new solid oral tablet of posaconazole, higher expo-
sures are achieved. TDM may still be indicated to prevent
overexposure, but currently available data are lacking to sub-
stantiate this application of TDM.
For isacuvonazole, there is no evidence available as it has
only recently been licensed by the FDA (EMA licensing is
still pending).
Despite all research on triazoles in the past decade, addi-
tional information with respect to pharmacokinetics and phar-
macodynamics of these drugs is needed to fully exploit the
concept of TDM for these drugs. In addition, the results of
prospective clinical TDM trials are warranted to substantiate
the value of TDM. Findings from hematology patients with
invasive aspergillosis (where the drugs are most applied) must
be translated to other populations (such as ICU, CF) and other
pathogens (Candida species, Mucor species). Only when we
have gained all this knowledge can we deploy this diagnostic
service to its best possible means.
Pharmacokinetics of Triazoles
All triazole agents possess different pharmacokinetic profiles.
Understanding the differences among agents in this class with
regard to absorption, distribution, metabolism, and elimina-
tion is essential in order to safely and effectively administer
these agents in the complex patient populations at risk for
fungal infection. It is also important to appreciate the differ-
ences between pharmaceutical formulations of a given drug,
since these can be used in one’s advantage (Fig. 1).
Similarly, the pharmacokinetic behavior of antifungals in
specific subpopulations must be known. Pharmacokinetic
studies typically use healthy volunteers or highly selected pa-
tients and focus on the average value of a parameter in the
group (i.e., the mean plasma concentration time profile). In
such studies, restrictive inclusion/exclusion criteria and con-
trolled designs are often used to increase the internal validity
of study findings. However, doing so may obscure the inter-
individual variability in pharmacokinetics and clinical infor-
mation on variability that will occur in clinical use. Focusing
on a single variable (e.g., renal function) in a traditional phar-
macokinetic study also makes it difficult to study interactions
among variables.
In practice, however, certain demographic, pathophysio-
logic, and therapeutic features, like body weight, excretory
and metabolic functions, and the administration of other ther-
apies, can regularly alter dose-concentration relationships. By
performing population pharmacokinetics, one is able to iden-
tify the measurable pathophysiologic factors that cause chang-
es in the dose-concentration relationship and the extent of
these changes.
With regard to azole therapy, insufficient population phar-
macokinetic data are available for various subpopulations of
patients. Specifically, there are limited data in intensive care
unit patients, cystic fibrosis patients for both voriconazole and
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posaconazole. Voriconazole pharmacokinetic data are well
documented in pediatric patients, but data on posaconazole
in this population are lacking. Fortunately, a vast amount of
pharmacokinetic data for posaconazole and voriconazole in
adult hematology patients exist [9, 27–33]. Data on
isavuconazole are not yet extensively available.
These data are urgently needed to build population phar-
macokinetic models and to reveal factors associated with var-
iation in specific populations that can assist in decision-mak-
ing. Once population parameters are known, interpretations
for an individual patient can be made to help define optimal
dosing regimens needed to achieve predefined target.
Furthermore, it helps in interpretation of results returned from
the pharmaceutical laboratory. This aspect is addressed with
antifungal therapeutic drug monitoring.
Pharmacodynamics of Triazoles: Clinical
Breakpoints
Patients achieving high concentrations of azole drugs may
show improved response to therapy but may also be at higher
risk for toxicity. Conversely, patients achieving lower concen-
trations may have reduced therapeutic response but subse-
quently be at lower risk for adverse events. The safe and
effective target concentrations (or Btherapeutic window^) for
most antifungals have not been definitely established. The
questions remain: how can one identify those breakpoints that
best fit the population at risk or having invasive fungal
disease?
Many large trials have not addressed the relation between
dose and effect [34–38]. Ideally, studies, particularly those
involving the azoles should include a (post hoc) pharmacoki-
netic and pharmacodynamic analysis to identify a relation
between concentration and effect or toxicity and help define
initial estimates for target concentrations because dose does
not correlate with plasma concentrations for voriconazole and
posaconazole. Without these trials being, it is almost impossi-
ble to identify clinical breakpoints.
There is an important need for regulatory agencies to re-
quire such analyses from the pharmaceutical industry thereby
providing more insight into possible clinical breakpoints. To
date, with a few exceptions, a gap exists in that few pharma-
ceutical industry research initiatives are designed to conduct
such research [7, 28, 39]. Commercially, the need to conduct
TDM carries a negative perception because it adds to the cost
of using the drug. Conversely, clinically, TDM is viewed pos-
itively because it is a tool used to further improve individual
therapy.
The Need for TDM Trials for Antifungal Drugs
More studies are warranted to assess the value of TDM of
antifungal drugs in both the setting of primary or secondary
prophylaxis and primary or salvage treatment. Avoriconazole
TDM trial in the setting of invasive aspergillosis is ongoing in
the Netherlands, but voriconazole TDM also needs to be val-
idated in the setting of prophylaxis.
With the advent of newer dosage forms presents the ideal
opportunity to start a posaconazole international TDM trial
investigating and validating the clinical breakpoints of
posaconazole for prophylaxis and therapy. An international
trial rather than one limited to one country would be needed
because large numbers of patients will be required to make
valid statements regarding prophylaxis cutoff values as well as
therapeutic targets. When initiating a TDM trial to validate
clinical breakpoints, it is crucial not to start to early as prelim-
inary breakpoints may change with emerging evidence.
Such trials should also not be delayed, because eventually
all physicians may become acquainted with TDM of
posaconazole even when it is not warranted. When such
familiarity is reached, performing a TDM study may be
considered unethical.
Knowledge on the population pharmacokinetics and covariates
Knowledge on the pharmacodynamics (breakpoints) 
Validation in clincal trials of defined breakpoints 
Translation to other populations and pathogens with confirmation
in similar trial design 
Safegaurding all requirements in daily practice  for execution of 
TDM (pre-analytical, analytical, post-analytical aspects)
Fig. 1 Requirement for a good
application of the TDM service
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Translation of TDM Knowledge into Clinical
Practice: How to Translate Findings from TDM
in One Host with One Bug, to Another Host
with Another Bug?
Once the results from the TDM trial in, for instance, hematol-
ogy patients with invasive aspergillosis are obtained, how do
such data translate to other populations like intensive care
patients with invasive aspergillosis or to hematology patients
with an invasive candidiasis or a mucormycosis? Do the same
criteria and breakpoints still apply?
These questions are difficult to answer. Knowing the phar-
macokinetics in the target population by measuring plasma
concentrations will circumvent problems such as malabsorp-
tion or low plasma concentrations in patients with increased
volumes of distribution. Measuring plasma concentrations
will enablemaking preventivemeasures to avoid subtherapeu-
tic exposure or unnecessary toxicity. Performing TDM will
help address pharmacokinetic differences between different
patient populations.
Differences in pharmacodynamics are more difficult to ad-
dress. Ideally, the same study is performed in other popula-
tions and patients with other causative microorganisms. In
practice, the same breakpoints can be used for more suscepti-
ble species such as Candida albicans and perhaps for non-
neutropenic patients, in whom the immune system and anti-
fungal therapy will target the invasive mycosis. Yet, this will
not provide the ultimate scientific evidence, and other chal-
lenges may exist including how to deal with polymicrobial
infections, microorganisms with reduced susceptibility, and
patients with combination therapy.
As there are two pharmacodynamic endpoints, one for ef-
ficacy against the pathogen and one for human toxicity, atten-
tion must be paid also to the latter. With regard to toxicity,
subjective translations from one population to another are
more straightforward.
Even if the ideal TDM study for every condition has been
conducted, it should be noted that the notion of a therapeutic
range is more a probabilistic concept than an absolute entity. It
represents a range of drug concentrations within which the
probability of a desired clinical response is relatively high
and the probability of unacceptable toxicity is relatively low.
In addition, extrapolating findings based on population re-
search to the individual is challenging. Some patients respond
effectively below the therapeutic range, whereas others need
concentrations above it. Similarly, some patients experience
toxic reactions within the therapeutic range. Common sense
and sound clinical judgment must remain the cornerstone of a
patient’s treatment, and TDM is a diagnostic tool that may
help explain the clinical course of a patient.
TDM as a Process
Performing TDMmust be considered as a complex process in
which all phases must be known to the users involved (Fig. 2).
Specifically, TDM must be considered a multidisciplinary
process. All professionals involved, from nursing staff and
physicians to analytical staff, pharmacologist, and pharmacist,
all carry specific responsibilities. Each and every one must be
aware of the interrelated steps that need to be most advanta-
geous setup to safeguard the proper use of TDM.
The clinician must use results from TDM to answer the
clinical question they raised when the measurement was or-
dered. Clinical pharmacists/pharmacologists can provide an
interpretation of plasma drug concentration and make recom-
mendations on how to optimize patient dosages. The clinical
microbiologist can provide input with regard to susceptibility
of cultured species. All three professionals must be acquainted
with the population for which the test is ordered and have
sufficient knowledge on the individual’s background. Only



















Fig. 2 TDM as a process: Bthe
total testing process^ with 3
components and 11 steps (adapted
and modified from [48]
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and microbiologist, the multidisciplinary approach of TDM of
antifungals can be beneficial.
Once established, adherence to guidelines on TDM is cru-
cial in obtaining the optimal result for the individual. TDM
emphasizes that pharmacokinetic-guided dose recommenda-
tions should not be viewed simply as a numerical value for
plasma drug concentrations. Training and teaching of every-
body involved is thus an essential requirement and must be
done not only when setting up this service but moreover also
during the wide application of TDM.
The process of TDM involves basically three phases. These
phases involve a pre-analytical phase, an analytical phase, and
a post-analytical phase. Each individual phase is subdivided
into substages as illustrated in Fig. 2.
The Pre-analytical Phase How early can we draw a TDM
sample: The therapeutic range for a drug is based on steady-
state plasma concentrations. Concentrations drawn too soon
after a dosage regimen has been started or changed and may
provide misleading information. In the case of voriconazole, a
first sample can be drawn on day 3 of therapy. But for
posaconazole, steady-state conditions are only reached by
days 7–10. Earlier assessment of plasma concentrations will
facilitate making timely interventions and bring decisions to a
prior time point. An algorithm has been suggested to deter-
mine samples early after the start of therapy (day 3) and
targeting a lower concentration that will eventually result in
a final target concentration under steady-state conditions [7].
More importantly, software is now available for dose
predictions.
At What Time Point Should We Draw the Sample The
sampling time will influence outcomes from TDM specifical-
ly in drugs with a very short half-life such as voriconazole. In
previous studies, TDM sampling for voriconazole have often
been performed randomly, which makes interpretation of the
results difficult [24, 25]. The ultimate sampling scheme would
encompass a certain amount of sampling moments that would
best predict total exposure (area under the concentration ver-
sus time curve), but this method is considered unfavorable for
many reasons such as patient burden, required nursing time,
and complex logistics. In routine practice, the most common
sampling moment is just prior to the next dose (trough con-
centrations or Cmin). Using a single sample will reduce costs
and more importantly will reduce patients’ burden due to fre-
quent sampling. Since trough concentrations correlate with
exposure, this provides a measure that in clinical practice
can be easily introduced. Posaconazole has a very long termi-
nal half-life. Therefore, peak and trough concentrations differ
minimally, especially with frequent dosing (i.e., three or four
times daily). Sampling at trough concentrations is therefore
not necessary but may only be preferred from a practical point
of view.
The Analytical Phase The basis for clinical pharmacokinetic
research and TDM is the availability of an accurate, precise,
sensitive, and selective analytical method for the quantitative
determination of azole antifungal drugs and their metabolites
in plasma/serum, with additional methods for other matrices
such as plasma, urine, cerebrospinal fluid, and tissue if possi-
ble [40–42]. In addition, analytical methods for measurement
of free, protein unbound antifungal drugs will provide insight
into the amount of protein binding under certain circum-
stances and enable the measurement of active drug, since only
free drug can exert a pharmacological effect. Assays have to
be validated according to the current requirements for valida-
tion of bioanalytical assays [34]. To help identify sources of
errors and to further improve analytical methods, participation
in an ongoing proficiency testing program is recommended
[35]. Results from a recent 5-year analysis of an international
proficiency testing program show that 1 out of 5 analyses lie
outside the predefined range of 80 to 120 % of the weighed-in
concentrations indicating an improper report on the concen-
tration [36]. The performing laboratory is the main determi-
nant of inaccuracy, suggesting that internal quality assurance
is pivotal in preventing inaccuracies, irrespective of the anti-
fungal drug measured, concentration, and analytical equip-
ment. There is a strong need for an ongoing proficiency testing
program to further improve the analytical methods for routine
patient management.
Post-analytical Phase Interpretation of the results can be
done preferably by a clinical pharmacist/pharmacologist who
is aware of all critical information as only then can a solid
advice be given. This information involves, among others,
knowledge on sampling time (directly after loading dosage
or during a steady state) and knowledge on the population
(neutropenic, CF, ICU), patient details (disease, phase of treat-
ment, mucositis, drug interactions), therapeutic range for the
specific population, and pathogen combination. Most impor-
tantly, the professional should maintain knowledge on devel-
opments and relevant discussion in literature. The advice from
the clinical pharmacologist must be brought into practice by
the clinician and the microbiologist must be informed (this can
be done in a wide variety of ways). Assuring adequate effect
on the patient is the clinician’s responsibility. Not achieving
the desired result must prompt repetition of the previous cycle
of steps.
Software that helps to define optimal dosing strategies are
currently available or under development (i.e., MwPharm,
DoseMe, BestDose). Using this software allows early clinical
decision-making as one does not have to wait until steady state
has been reached. The models defined will assist in making
predictions under steady-state conditions. In addition, with a
single or preferably multiple measurements that serve as prior
input, an area under the concentration time curve can be cal-
culated. All prior inputs will also serve for model refinement
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(for the population) and predictions for the individual done at
a later stage. Another advantage is that non-trough concentra-
tions can be used as input to predict extrapolated trough con-
centrations or AUC under the condition that administration
and sampling time are recorded adequately.
Lastly, the frequency of sampling remains subject to ongo-
ing debate. One single sample is not considered TDM and will
not provide the necessary input on a patient’s intraindividual
pharmacokinetic variability. When TDM is commenced, this
means multiple interventions over time are sometimes neces-
sary to achieve target concentrations to remain within the ther-
apeutic range. As mentioned previously, there is substantial
intraindividual variation in triazole drug concentrations over
time. Due to this high intrasubject variability, an optimal sam-
pling frequency has to be determined to timely adjust dose in
order to achieve concentrations within the target range. A
good starting point would be to perform TDM once or twice
a week shortly after initiation of therapy. This can be reduced
to once every 2 weeks when the patient is clinically improving
or even less frequent when the patient is no longer in the
hospital. Changes in clinical condition or when interacting
drugs are introduced may prompt for more frequent sampling
even when therapy has been given already for a longer period
of time.
Conclusion
TDM of Antifungal Drugs in the Future The issues
discussed provide opportunities for future research in the next
couple of years. But what about a long-term forecast? Where
will we stand in 10 years? Will all be the same or does the
current research help us to induce a change in the way TDM is
used? Again, several steps are crucial: (1) industry must fulfill
a prominent role in gathering data on breakpoints, (2) optimal
initial dosing regimens must be known for the specific sub-
population, (3) sample assessment must be brought to the
absolute earliest time after treatment initiation, and finally
(4) new sampling techniques must be developed to provide
the basis for continuous monitoring. All steps are detailed in
the next paragraph.
The Role of the Pharmaceutical Industry At this time
point, TDM is warranted since the current dosing regimens
do not fit the individual. Some antifungals have been licensed
at a dose that subsequently has been changed. For example,
both the adult and pediatric dosing guidelines of voriconazole
have changed since market introduction. This indicates that
some antifungals were marketed lacking sufficient data to
identify the optimal dosages in specific cohorts of patients.
Unfortunately, antimicrobial research has diminished for a
variety of reasons [37]. Investigator-initiated research lack
the scale needed to generate sufficient data. Therefore, the
pharmaceutical industry should perform large clinical trials
to further elucidate pharmacokinetic and pharmacodynamic
behavior of drugs in special patient populations. Large clinical
trials need to incorporate pharmacokinetic research instead of
only investigating the effect of dose on outcome [38, 43–45].
It is unclear from these studies if failure to respond to therapy
originates from underexposure or toxic exposure since plasma
concentrations are unknown. This research should be per-
formed before or very short after market authorization.
Delay At the moment, TDM can be considered a diagnostic
tool. Diagnostics may be useful to detect a change in a clinical
condition such as an infection or in the case of TDM a sub- or
supra-therapeutic exposure. Unfortunately, diagnostics always
follow a change in clinical condition that necessitates frequent
monitoring. The inherent downside of TDM is the possible
delay in first-time assessment as well as follow-up assess-
ments. This may be due to pharmacokinetic aspects (i.e.,
steady state not reached), cost aspects, as well the availability
of in-house testing facilities. A delay in the possibility to time-
ly determinate too low or too high exposure may have clinical
consequences. It has been repeatedly shown that delay in the
initiation of antifungal therapy and inadequate exposure are
independently associated with increased hospital mortality.
Upfront Adequate Dosing We must orchestrate our knowl-
edge derived from population pharmacokinetic models to seek
for a probabilistic (or stochastic) model to upfront give the
patient the optimal dose based on specific patient features
(identified covariates). This implies that we would switch
from TDM as a concentration-guided dosing tool to an ap-
proach where the drug concentration could be used as a vali-
dation set of an individualized dosing advice and thereby
bringing it to earlier time point with subsequent reduction in
host risk. Also, whenever possible, an attempt should be made
to integrate pharmacodynamic parameters such as a patho-
gen’s MIC. This approach, with a tailored dose followed by
validation of target concentrations, will be performed very
soon (i.e., 2 or 3 days) after the start of therapy. Inherent to
whatever new approach is chosen, we may not be able to
identify all factors that cause changes in PK/PD. In other
words, a residual error will always be present and unforeseen
changes in the clinical situation will prompt for new assess-
ments of concentrations. But I strongly believe that we should
put effort into bringing this diagnostic tool to an earlier time
point after initiation of therapy with a tailored dose.
New Sampling Techniques Unfortunately, many times sam-
pling refrains to the setting of clinical monitoring and the
patients are lost to follow-up after leaving the hospital. Also,
monitoring in a home-based setting might be hindered by the
difficulty of obtaining easy venous access, patient discomfort,
technical issues such as instability of the drug sample, and
Curr Fungal Infect Rep (2015) 9:122–129 127
logistical problems. All these may be solved by applying the
new sampling technique termed dried blood spot (DBS) sam-
pling. In DBS sampling, blood is obtained via a finger prick
with an automatic lancet. With clear instructions and after
adequate training, patients administer this finger prick them-
selves. The sample is then dried and sent by regular post to the
laboratory for analysis. The technique is well established for
applications such as neonatal screening for inborn diseases,
but has recently experienced a surge of interest in the context
of therapeutic drug monitoring (TDM). This technique is very
suitable not only for continuous monitoring at home but also
for the purpose of pharmacokinetic research outside the hos-
pital. Furthermore, it allows clinicians and other health care
workers who do not have access to onsite facilities to send the
samples by regular mail to a reference laboratory. Currently,
the Radboudumc has such an assay available supporting this
approach. Other similar initiatives have been reported in liter-
ature [46, 47].
In summary, clinical pharmacological research of antifun-
gal drugs remains highly relevant for the individualization of
treatment of patients. The challenges of TDM of antifungal
drugs in a wide cohort of patients provide an interesting op-
portunity and challenge for future research to further optimize
the individual’s treatment. Knowledge on each individual step
in this process, and the optimization of these steps, will allow
for optimal application of this diagnostic service.
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